Differentiating Progressive Supranuclear Palsy and Parkinson's Disease With Head-Mounted Displays
Arvid Herwig1,2, Almedin Agic3, Hans-Jürgen Huppertz4
1Department of Psychology, Clinical Psychology and Psychotherapy, University of Bremen, Bremen, Germany.
Frontiers in Neurology
|January 10, 2022
Summary
Head-mounted eye-tracking effectively distinguishes Progressive Supranuclear Palsy (PSP) from Parkinson
Area of Science:
- Neuroscience
- Ophthalmology
- Medical Diagnostics
Background:
- Progressive Supranuclear Palsy (PSP) presents early diagnostic challenges, often mimicking Parkinson's Disease (PD).
- Accurate differentiation is crucial for timely and appropriate patient management.
- Current diagnostic methods can be invasive or lack standardization.
Purpose of the Study:
- To evaluate the efficacy of eye-tracking technology within Head-Mounted Displays (HMDs) for distinguishing PSP from PD.
- To develop a standardized, accessible diagnostic tool for early-stage neurodegenerative diseases.
Main Methods:
- Saccadic eye movements were recorded using HMDs in patients with PSP, PD, and healthy controls (HCs).
- High-resolution MRI with atlas-based volumetric analysis assessed brain structures.
- A novel diagnostic index was calculated based on vertical and horizontal saccade parameters.
Main Results:
- PSP patients exhibited distinct abnormalities in vertical saccade velocity and gain.
- The derived diagnostic index achieved high sensitivity (77%) and specificity (93%) in differentiating PSP from PD.
- Significant correlations were found between oculomotor measures and midbrain volume in PSP patients.
Conclusions:
- HMD-based eye-tracking offers a standardized and user-friendly method for differentiating PSP from PD and HCs.
- This technology can significantly aid in the early and accurate diagnosis of PSP.
- Oculomotor abnormalities correlate with specific neuroanatomical changes in PSP.
Related Concept Videos
Parkinson's Disease: Overview
808
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
808
Parkinson's Disease: Treatment
435
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
435
Neural Regulation
40.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.5K


